Join us for our upcoming webinar:  New Frontiers in Epigenomic Analysis - from Probing Disease Progression to Enhancing Sequencing Methodologies

View this email as a web page here.
  
Please join us for our upcoming webinar entitled:

New Frontiers in Epigenomic Analysis – from Probing Disease Progression to Enhancing Sequencing Methodologies

Insight into epigenetic modifications has the capability to elucidate mechanisms governing disease progression and resistance, enabling the identification of biomarkers that can provide diagnostic insight and serve as targets for novel classes of therapeutics. Technological advances have facilitated broad profiling of epigenetic modifications across the genome, while allowing application to higher numbers of samples. This webinar will include presentations and a panel discussion and will cover state-of-the-art sample preparation techniques that leverage sequencing readouts for genome-wide surveying across a range of epigenetic factors, including transcription factor binding sites, histone modifications, chromatin organization, nucleosome mapping, and methylation profiling. The application of these technologies in translational research settings to gain novel insight into the role of epigenetic factors in cancer will also be explored.

Please also join us after the presentations for an opportunity to engage in a panel discussion with our speakers.

Wednesday, October 13th 1:00 PM EST
Register Here
Leveraging epigenomic tools in technically challenging scenarios
Rohit Chandwani, M.D., Ph.D., Weill Cornell Medicine
The organization of chromatin is central to nuclear processes of replication, repair, and transcription. Rapid advances in sequencing technologies have enabled characterization of epigenomic states at unprecedented scale and resolution. Every layer of organization from histone modification to nucleosome occupancy to both short- and long-range chromosomal interactions can now be ascertained more readily. However, the deployment of these tools has been uneven across tissue types, cell numbers, and form of tissue storage. Herein we describe our efforts to bring epigenomic tools to the most recalcitrant of starting inputs as part of our investigations in cancer epigenetics.

Next generation genomic mapping with CUTANA CUT&RUN
Michael-Christopher Keogh, Ph.D. Chief Scientific Officer, Epicypher Inc.
EpiCypher has pioneered the manufacture of semi-synthetic nucleosomes containing fully defined histone post-translational modifications (PTMs). These represent a physiological target for chromatin studies and have now been used for multiple approaches, including dissecting epigenetic regulators (the dCypher platform) and standardizing ChIP from antibody characterization to normalization (the SNAP platform). CUTANA (our expansion of the CUT&RUN / CUT+Tag approaches) is the next horizon for genomic mapping, and dramatically increases sensitivity with reduced cell numbers and sequencing depth. Further this approach is now being increasingly controlled with nucleosome standards. The insights gained from each platform will be discussed.

Functional epigenomics of cancer progression
Kunal Rai, M.D., Anderson Cancer Center
Epigenomic aberrations have emerged to be a key feature associated with cancer progression, however, whether these events could be utilized for personalized medicine is less well understood. My lab focuses on comprehensive epigenomic analyses from patient samples using high-throughput nano ChIP-Seq followed by chromatin state determination, Hi-C/HiChIP-based chromatin structure profiling as well as single-cell epigenomic approaches. We have recently shown that epigenome content of tumors can be exploited to predict immunotherapy response in melanoma and to stratify patients into groups which respond to specific targeted therapies in colorectal cancers. Finally, we have identified novel epigenomic subgroups in pan-cancer chromatin state studies that display specific biological insights and responses to targeted therapies.

NEBNext® Enzymatic Methyl-seq (EM-seq): A high-performance alternative to bisulfite sequencing for methylome analysis
Chaithanya Ponnaluri, Ph.D., New England Biolabs
The cytosine modifications 5¬methylcytosine and 5¬hydroxymethylcytosine are important regulatory marks and their identification within genomes is essential in understanding gene regulation. Bisulfite sequencing (BS) has been the gold standard for detecting these modifications, however, the chemical bisulfite reaction damages and fragments DNA, resulting in smaller insert sizes and coverage bias in sequencing data. To overcome these drawbacks, we developed a sequencing method called NEBNext Enzymatic Methyl-seq (EM-seq) for the Illumina platform. This method is exclusively enzyme based and is less damaging to DNA than bisulfite conversion enabling longer insert sizes, lower duplication rates and minimal GC bias. EM-seq's more even coverage allows a higher percentage of CpGs to be assessed leading to more consistent evaluation of methylation across genomic features (TSS, CpG island, etc.). EM-seq is more robust than bisulfite sequencing, works over a wide range of DNA input amounts, has superior sequencing metrics, and detects more CpGs.

New England Biolabs is a Certified B Corporation.

   

New
Products
Special
Offers
Technical
Support
Customer
Feedback

One or more of these products are covered by one or more patents, trademarks and/or copyrights owned or controlled by New England Biolabs, Inc. For more information, please email busdev@neb.com. The use of these products may require you to obtain additional third party intellectual property rights for certain applications.

Your purchase, acceptance, and/or payment of and for NEB's products is pursuant to NEB's terms of sale. NEB does not agree to and is not bound by any other terms or conditions, unless those terms and conditions have been expressly agreed to in writing by a duly authorized officer of NEB.

B Corporation is a trademark of B Lab, Inc.

© Copyright 2021, New England Biolabs, Inc.; All rights reserved.

New England Biolabs is an ISO 9001, ISO 14001 and ISO 13485 certified facility.

 

 

Never miss an email from The Scientist.
Click here to add The Scientist to your safe-sender list.

The Scientist, 1000 N West Street, Suite 1200, 
Wilmington, Delaware, United States, 19801  
Toll-Free: (888) 781-0328 | Phone: (705) 528-6888
Email: privacy@the-scientist.com

www.the-scientist.com

You received this email because you are subscribed to The Scientist Special Offers and Promotions from The Scientist.
Click to Unsubscribe | View Privacy Policy

Stop receiving email from The Scientist

 


Commentaires

Posts les plus consultés de ce blog

Chris Ramsey can take the heat, but what would relegation for QPR mean for black managers in the Premier League?

Luke from 'Gilmore Girls' is selling out and starting a coffee brand

Sandy Hook Parents Are Criticizing Megyn Kelly For Giving A Platform To ‘Truther’ Alex Jones